Celladon Corporation is a development stage biotechnology company focused on developing treatments for cardiovascular diseases.
Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new biotechnological tools, have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular therapeutics.
Celladon's first generation product enhances calcium cycling in the heart, delivered via a recombinant adeno-associated viral (rAAV) vector, as a treatment for congestive heart failure.
 |
Clinical Trials Continue Sharp Memorial Hospital and San Diego Cardiac Center are participating in Celladon's first-ever human gene transfer therapy clinical trial in patients with heart failure. Three patients have already been treated at Sharp Memorial since the trial began in May and the trial continues to recruit candidates. |
|
